PiVily Quarterly Report
Standards caught up with the operating reality
Global ICSR and real-world evidence standards advanced while EU guidance sharpened expectations around privacy and embryo-fetal risk minimisation.
The quarter in one reading
Q3 2025 was a standards quarter. The important movement was not novelty for its own sake, but formal guidance addressing the kinds of data, channels and risk contexts PV systems already had to manage.
This retrospective edition was reconstructed from official materials and completed on 11 August 2026. It describes the quarter; it does not imply contemporaneous publication.
Material signals
What moved—and why it mattered.
ICH E2D(R1) updated the language of post-approval case management.
ICH E2D(R1) reached Step 4 in September 2025, revising definitions and standards for post-approval safety data and the management and reporting of individual case safety reports.
The implementation burden sits in definitions, intake pathways, case-management rules, training and system behaviour. Alignment requires more than updating a procedure title.
Has the impact assessment traced each changed concept through sources, decisions, systems, vendors, local procedures and training?
ICH M14 established a common methodological floor for safety studies.
ICH M14 reached Step 4 in September 2025, providing principles for planning, designing, analysing and reporting non-interventional studies using real-world data for medicine-safety assessment.
Harmonisation reduces avoidable variation, but it does not remove the need to justify data relevance, reliability, design choices and limitations for the regulatory question.
Is the organisation ready to apply one methodological position while tracking different regional implementation dates and expectations?
Privacy and risk-minimisation guidance became more explicit.
EMA made GVP Module VI Addendum II on masking personal data in ICSRs legally effective in July 2025 and Module XVI Addendum I on risk minimisation for embryo-fetal risks legally effective in August 2025.
Both changes show the same operating principle: safety systems must protect individuals and make risk controls precise without damaging the scientific usefulness or traceability of the information.
Are privacy and risk-minimisation controls tested for both compliance and their effect on usable safety information?
Regulators began documenting AI use, not only discussing it.
EMA and HMA published their first annual AI Observatory materials in July 2025, compiling regulatory-network experience and horizon scanning across the medicines lifecycle.
The signal was institutional learning: regulators were building a mechanism to observe actual use, identify gaps and prepare for more specific governance needs.
Does the organisation capture lessons from AI use in a form that can change controls, or only track deployment?
Next-quarter watch
Questions to carry forward.
- Regional implementation of ICH E2D(R1) and M14
- Training, systems and vendor changes required by revised case-management concepts
- More specific methods for evaluating risk-minimisation effectiveness
Method & source register
Trace the reading back to the record.
PiVily selects developments for system-level relevance to human pharmacovigilance. Facts are attributed to official publishers; interpretation is editorial. This is not an exhaustive jurisdictional change log or organisation-specific advice.